


PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

 ■ L1
 Identity

 ■ L2
 Purity

 ■ L3
 Net Peptide Content

 ■ L4
 Sterility

 ■ L8
 Fentanyl Screen

Sample & Vial Validation


MORE VIEWS OF VIAL A



Brand	APEXX BIOLABS LLC	Product	BPC-157
Lot / Batch	T-BPC-0032	Label Claim	10 mg
Matrix	lyophilized powder	Sample Count	1
Cap Color	Black	Crimp Color	Silver / Aluminum
Contents Color	White	Seal Intact	Yes
Condition	sealed, intact	Received	Sep 24, 2026 PT
Sampling	client submitted		

Test Results

Test	Specification	Result	
Identity research screen	every vial within ± 1 Da of 1419.556 Da	1419.573 Da	PASS
Purity research screen	≥ 99.25 area %	99.57%	PASS
Net Peptide Content research screen	every vial within $\pm 10\%$ of 10 mg	Vial A: 10.47 mg	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	Target DNA not detected	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	none detected	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.



Layer Results

1

Identity

LC-MS (ESI+)

1419.573 Da

every vial within ± 1 Da of 1419.556 Da

PASS

Theoretical mass

1419.556 Da

Acceptance

within ± 1 Da

Vial A

1419.573 Da · PASS

1419.573 Da PASS

2

Purity

RP-HPLC 214nm (USP 621)

99.57%

≥ 99.25 area %

PASS

Acceptance

$\geq 99.25\%$

Vial A

99.57% · PASS

Criterion

Axiom Analytics SPEC-PURITY-001, Revision 1, effective

source

2026-08-31

99.57% PASS

limit 99.25%

3

Net Peptide Content

Quantitative HPLC vs reference std

Vial A: 10.47 mg

every vial within $\pm 10\%$ of 10 mg

PASS

Target

10 mg ($\pm 10\%$)

Vial A

10.47 mg · PASS

Confirmed container volume

Unknown

Content concentration

Unknown

10.47 mg PASS

4

Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected

Rapid PCR screen

PASS

Result

Target DNA not detected

Acceptance

Rapid PCR screen



CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)



Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-2898-W7B5

BPC-157 · Lot T-BPC-0032
Issued Oct 16, 2026 PT · v1
Verify: 7107-232F-98A6



SCAN TO VERIFY

8

Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected

no fentanyl or analog at or above 1 ng/mg

PASS

Result	Not detected	Detection limit	1 ng/mg
Analytes screened	Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)	Source container	A

Reporting Scope & Limitations

[Sterility · Rapid PCR] DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

[Fentanyl Screen] Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	Alana Reeves	Analyst Signature	ed25519:1222f76754f0daf8263f015...
Technical Reviewer	Michael Niles	Reviewer Signature	ed25519:08cc30c490974f7dcec6fdb8...
Laboratory Director	Daniel Brennan	Director Signature	ed25519:5bed5c74a6add7f138a65049...

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-2898-W7B5>.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: e6ff834b6791437169f8685ae666bb2316af79018174504f08935a2deb7e10c3...

Seal: ed25519:64a5cce5004c60d480889e5f7fd71fe8f07be068...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.